Milind M. Javle, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study results showing that the novel tyrosine kinase inhibitor infigratinib may prove to be effective in treating patients with advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement (Abstract 265).
Tenna V. Henriksen, PhD Candidate, of Aarhus University, discusses her findings on how circulating tumor DNA may help assess recurrence risk and the benefit of adjuvant therapy, and more quickly detect early relapse after treatment in patients with colorectal cancer (Abstract 11).
Rutika Mehta, MD, MPH, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the 3-year regression-free and overall survival results from the JACCRO study, which compared the efficacy of S-1, an oral prodrug of fluorouracil, vs S-1 plus docetaxel after curative resection of stage III gastric cancer (Abstract 159).
Talia Golan, MD, of the Oncology Institute, Sheba Medical Center, discusses phase III results from the POLO trial, which explored the question of whether maintenance olaparib could improve overall and progression-free survival for patients with germline BRCA-mutated metastatic pancreatic cancer (Abstract 378).
Afsaneh Barzi, MD, PhD, of the City of Hope Comprehensive Cancer Center and the University of Southern California, discusses reasons for the incomplete understanding of the molecular landscape of minority patients with cancer, lack of screening chief among them. This underrepresentation, Dr. Barzi says, is more marked in gastrointestinal malignancies than other solid tumors, and she recommends ways to improve the outlook.
Thierry André, MD, of Hôpital Saint-Antoine, discusses results from the GARNET study, which showed that dostarlimab, an anti–PD-1 antibody, demonstrated durable antitumor activity in patients with mismatch repair–deficient colorectal and noncolorectal solid tumors. No new safety signals were detected, and most treatment-related adverse events were of a low grade (Abstract 9).
